OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates
“Our Series B financing round progressed rapidly, and we deeply appreciate our investors’ recognition of our Company and continual support,” said Dr. Yang Liu, Co-Founder, Chairman of the Board, CEO and CSO of OncoC4. “We are committed to rigorously advancing the global development of our core pipeline, while strategically expanding business development activities, with the ultimate goal of delivering more disruptive therapies to patients worldwide.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.